Starting January 2026, the NHS will provide a new layer of protection against chickenpox for children in the UK, marking a significant advancement in public health strategy. The varicella vaccine, now incorporated into the standard childhood immunisation schedule, aims to safeguard younger generations while also offering a catch-up programme for older children.
Understanding Chickenpox: Symptoms and Transmission
Chickenpox is an exceedingly contagious illness caused by the varicella zoster virus (VZV). It spreads easily through direct contact or via airborne droplets from sneezes and coughs. While it predominantly affects young children—about half have contracted the virus by their fourth birthday—individuals of any age can be susceptible if they have not previously had the illness.
Symptoms typically begin with a fever, muscle aches, and a general sense of malaise. Following these initial signs, a distinctive itchy rash emerges, presenting as red or pink spots that can appear anywhere on the body, including the mouth. Depending on the individual, the rash may be mild, with just a few spots, or extensive, covering the body entirely. The spots transform into fluid-filled blisters, then crust over into scabs that eventually fall off. Contagion can occur from two days prior to the onset of the rash until all spots have scabbed, usually around five days after their appearance.
The New Vaccine: MMRV and Its Benefits
The newly introduced vaccine, known as MMRV, combines protection against measles, mumps, rubella, and varicella (chickenpox). Children born after 1 January 2026 will automatically receive two doses of the MMRV vaccine at 12 and 18 months. A comprehensive catch-up programme will also be available for older children, with specific guidelines based on birth dates:
– Children born on or after 1 January 2025: Two doses at 12 and 18 months.
– Children born between 1 July 2024 and 31 December 2024: Two doses, with one at 18 months and another at age 3 years and 4 months.
– Children born between 1 September 2022 and 30 June 2024: One dose at age 3 years and 4 months.
– Children born between 1 January 2020 and 31 August 2022: A single dose later in 2026.
Families will be contacted by their GP surgeries to arrange vaccination appointments.
Experts anticipate that the inclusion of the varicella vaccine in routine immunisations will significantly decrease the incidence of chickenpox, thus reducing severe cases. While the vaccine does not guarantee lifelong immunity, it substantially lowers the chances of contracting the illness or experiencing severe symptoms. Serious side effects, such as allergic reactions, are rare. However, as it is a live vaccine containing a weakened version of the virus, it is not advised for individuals with compromised immune systems.
Aligning with Global Health Practices
This initiative aligns the UK with several countries, including Germany, Canada, Australia, and the United States, which already provide routine varicella vaccinations. Concerns previously held about vaccinating children leading to increased cases of shingles have been dispelled by recent long-term studies from the United States.
The Joint Committee on Vaccination and Immunisation (JCVI) recommended the MMRV vaccine for all children in November 2023, and the government confirmed its introduction in August 2025. This move comes in response to concerning data revealing that childhood vaccine uptake rates had not reached the desired 95% target, with only 91.9% of five-year-olds receiving one dose of the MMR vaccine—the lowest level since 2010.
The Risks of Chickenpox
While the majority of chickenpox cases in children are mild, the illness can still lead to significant discomfort and necessitate time away from school or nursery. In rare situations, complications can arise, such as encephalitis (brain swelling), pneumonitis (lung inflammation), and even stroke, which may require hospitalisation and, in extremely rare cases, can be fatal. Chickenpox poses heightened risks for infants and adults, and can lead to severe complications during pregnancy.
The Shingles Connection and Vaccination Options
Shingles is a painful condition that can emerge later in life in individuals who have previously had chickenpox. The virus remains dormant in the body and can reactivate, especially when the immune system is weakened due to stress or other medical conditions. Symptoms typically manifest as a painful rash, frequently located on one side of the body.
To mitigate the risk of developing shingles, the NHS provides a vaccine for specific demographics, including individuals aged 65 and over, those aged 70 to 79 who have not been vaccinated, and anyone aged 50 and above with a severely weakened immune system. It’s vital to receive the shingles vaccine even if one has previously experienced the condition, as the vaccine can significantly lessen the severity of symptoms.
Why it Matters
The introduction of the chickenpox vaccine into the NHS childhood immunisation programme is a crucial public health measure that not only aims to protect individual children from a common but sometimes serious illness but also seeks to lower overall infection rates across the population. By ensuring that children receive this vaccine, the NHS is taking a proactive step towards reducing the burden of chickenpox and its complications, ultimately contributing to healthier futures for all children in the UK.
